文献速递神经免疫

利妥昔单抗与奥瑞利珠单抗治疗复发缓解型多发性硬化比较

Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis.
PubMed 文献 · JAMA Neurol · 2023-01-01

这项观察性队列研究纳入1613例复发缓解型多发性硬化患者,经倾向评分匹配后比较利妥昔单抗与奥瑞利珠单抗的疗效。结果显示利妥昔单抗组年复发率高于奥瑞利珠单抗组(0.20 vs 0.09,率比1.8,95%CI 1.4-2.4,P<.001),未显示非劣效性;两组残疾累积风险无差异。

要点

  • 利妥昔单抗组年复发率0.20,奥瑞利珠单抗组0.09,率比1.8(95%CI 1.4-2.4,P<.001)。
  • 利妥昔单抗组复发累积风险高于奥瑞利珠单抗组(HR 2.1,95%CI 1.5-3.0)。
  • 两组6个月确认的残疾累积风险无差异。

核心结论

  • 在这项非劣效性比较效果观察性队列研究中,结果未显示利妥昔单抗相对于奥瑞利珠单抗的非劣效性。
  • 在日常实践中,利妥昔单抗与奥瑞利珠单抗相比与更高的复发风险相关。
  • 利妥昔单抗和奥瑞利珠单抗以统一剂量和间隔给药的疗效正在随机非劣效性临床试验中进一步评估。

研究设计与样本

  • 观察性队列研究,于2015年1月至2021年3月开展,患者来自MSBase登记处和丹麦多发性硬化登记处(DMSR)。
  • 纳入有复发缓解型多发性硬化病史、接受奥瑞利珠单抗或利妥昔单抗治疗、随访至少6个月且有足够数据计算倾向评分的患者。
  • 基线特征可比的患者按倾向评分以1:6匹配,匹配变量包括年龄、性别、多发性硬化病程、残疾(扩展残疾状况量表)、既往复发率、既往治疗、疾病活动(复发、残疾累积或两者)、磁共振成像病灶负荷(缺失值插补)和国家。

主要发现

  • 6027例接受奥瑞利珠单抗或利妥昔单抗治疗的多发性硬化患者中,1613例(平均[SD]年龄42.0[10.8]岁;1089例女性[68%])符合纳入标准并纳入分析(898例来自MSBase,715例来自DMSR)。
  • 710例接受奥瑞利珠单抗治疗的患者(414例来自MSBase,296例来自DMSR)与186例接受利妥昔单抗治疗的患者(110例来自MSBase,76例来自DMSR)匹配。
  • 在配对删失的平均(SD)随访1.4(0.7)年期间,利妥昔单抗治疗患者的年复发率高于奥瑞利珠单抗治疗患者(率比1.8;95%CI 1.4-2.4;年复发率0.20 vs 0.09;P<.001)。
  • 利妥昔单抗治疗患者的复发累积风险高于奥瑞利珠单抗治疗患者(风险比2.1;95%CI 1.5-3.0)。
  • 两组间残疾累积风险无差异,结果在敏感性分析中得到确认。

关键数值与推荐

  • 主要终点为年复发率的非劣效性比较,预设非劣效性界值为率比1.63。
  • 年复发率:利妥昔单抗组0.20 vs 奥瑞利珠单抗组0.09(率比1.8;95%CI 1.4-2.4;P<.001)。
  • 复发累积风险:利妥昔单抗组 vs 奥瑞利珠单抗组(风险比2.1;95%CI 1.5-3.0)。
  • 6个月确认的残疾累积:两组间无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Ocrelizumab, a humanized monoclonal antibody targeted against CD20+ B cells, reduces the frequency of relapses by 46% and disability worsening by 40% compared with interferon beta 1a in relapsing-remitting multiple sclerosis (MS). Rituximab, a chimeric monoclonal anti-CD20 agent, is often prescribed as an off-label alternative to ocrelizumab. OBJECTIVE: To evaluate whether the effectiveness of rituximab is noninferior to ocrelizumab in relapsing-remitting MS. DESIGN, SETTING, AND PARTICIPANTS: This was an observational cohort study conducted between January 2015 and March 2021. Patients were included in the treatment group for the duration of study therapy and were recruited from the MSBase registry and Danish MS Registry (DMSR). Included patients had a history of relapsing-remitting MS treated with ocrelizumab or rituximab, a minimum 6 months of follow-up, and sufficient data to calculate the propensity score. Patients with comparable baseline characteristics were 1:6 matched with propensity score on age, sex, MS duration, disability (Expanded Disability Status Scale), prior relapse rate, prior therapy, disease activity (relapses, disability accumulation, or both), magnetic resonance imaging lesion burden (missing values imputed), and country. EXPOSURE: Treatment with ocrelizumab or rituximab after 2015. MAIN OUTCOMES AND MEASURES: Noninferiority comparison of annualized rate of relapses (ARRs), with a prespecified noninferiority margin of 1.63 rate ratio. Secondary end points were relapse and 6-month confirmed disability accumulation in pairwise-censored groups. RESULTS: Of the 6027 patients with MS who were treated with ocrelizumab or rituximab, a total of 1613 (mean [SD] age; 42.0 [10.8] years; 1089 female [68%]) fulfilled the inclusion criteria and were included in the analysis (898 MSBase, 715 DMSR). A total of 710 patients treated with ocrelizumab (414 MSBase, 296 DMSR) were matched with 186 patients treated with rituximab (110 MSBase, 76 DMSR). Over a pairwise censored mean (SD) follow-up of 1.4 (0.7) years, the ARR ratio was higher in patients treated with rituximab than in those treated with ocrelizumab (rate ratio, 1.8; 95% CI, 1.4-2.4; ARR, 0.20 vs 0.09; P < .001). The cumulative hazard of relapses was higher among patients treated with rituximab than those treated with ocrelizumab (hazard ratio, 2.1; 95% CI, 1.5-3.0). No difference in the risk of disability accumulation was observed between groups. Results were confirmed in sensitivity analyses. CONCLUSION: In this noninferiority comparative effectiveness observational cohort study, results did not show noninferiority of treatment with rituximab compared with ocrelizumab. As administered in everyday practice, rituximab was associated with a higher risk of relapses than ocrelizumab. The efficacy of rituximab and ocrelizumab administered at uniform doses and intervals is being further evaluated in randomized noninferiority clinical trials.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Roos I, Hughes S, McDonnell G, et al. Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis. JAMA Neurol. 2023. PMID: 37307006. doi:10.1001/jamaneurol.2023.1625

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。